Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
April 6th, 2024

Publishment of data from our pipeline
at the American Association for Cancer Research Annual Meeting 2024

Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancer, presented new data at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, in San Diego, California.

Regarding CTX-712, CLK inhibitor, a total of 46 patients with solid tumors and a total of 14 patients with hematologic malignancies were enrolled in the CTX-712-CL-01 study to evaluate the safety, pharmacokinetics (PK) / pharmacodynamics (PD) profile and preliminary efficacy as of data cutoff on November 20, 2023. Observed DLTs (Dose-limited Toxicity) were dehydration, platelet count decrease, and hypokalemia, and MTD (Maximum Tolerated Dose) was determined to be 140mg twice a week. Common any-grade-related adverse events were nausea and vomiting. Among all patients, partial responses were observed in 4 patients (4/46, 8.6%), who were all patients with ovarian cancers. (4/14, 28.6%). Among a total of AML and MDS patients (14), CR(Complete Remission) was observed in 3 patients, CRi (Complete Remission without incomplete hematologic recovery) was observed in 1 patient and MLFS (Morphologic Leukemia-Free State) was observed in 1 patient, so overall response rate is 42.9%. In PK analysis, a dose-dependent increase in systemic exposure of CTX-712 was overserved, and a dose-dependent increase of exon skipping in two maker RNAs that are extracted from peripheral blood cell demonstrated PD effect induced by CTX-712.

Regarding CTX-439, CDK12 inhibitor, we reported (1) pharmacodynamics (PD) markers to monitor the suppression of CDK12/13 in humans, (2) patient selection biomarkers to determine sensitivity to CTX-439, and a significant anti-tumor effect was revealed in PDX models that showed sensitivity in the survey, (3) a synergistic effect in combination with PARP inhibitors and other chemotherapy and molecular-targeted drugs. in vitro and in vivo.

Regarding GCN2, we reported that our candidate compound inhibiting the HRI/PERK/GCN2 triple kinase in cells observed a distinct anti-growth effect for Multiple Myeloma with resistant to proteasome inhibitors when combined with proteasome inhibitors in vitro and in vivo.

Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

<Overview of presentation at AACR 2024>

Presentation on CTX-712, CLK inhibitor

Abstract No	CT115
Title	A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort

Abstract No	CT110
Title	A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts

Abstract No	2081
Title	Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials

Presentation on CTX-439, CDK12 inhibitor

Abstract No	3301
Title	Translational Research of CDK12/13 Inhibitor, CTX-439, Informing Clinical Trial Strategy

Presentation on GCN2 inhibitor

Abstract No	1233
Title	Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma

About CTX-712

CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays an important role in cell growth. For more information, please visit: jRCT2080224127 for details on the Japan phase 1 clinical trial and clinicaltrials.gov/ (NCT05732103) for details on the US Phase 1/2 clinical trial of CTX-712.

About Chordia Therapeutics

Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, is developing novel cancer therapies. Chordia's lead asset, CLK inhibitor CTX-712, is currently in Phase 1 clinical study in Japan and Phase1/2 clinical study in the US. CTX-712 potentially targets vulnerabilities in cancer and could benefits patients with various types of cancer. In addition to CTX-712, Chordia is researching several preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

Established:	November 2017
Address:	26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Representative:	Hiroshi Miyake, Representative Director
Website:	https://www.chordiatherapeutics.com/en/

For more information, please contact Mizobe in IR: ir@chordiatherapeutics.com